M-A: Non-steroidal anti-inflammatory drugs, intravenous fluids, pancreatic stents, or their combinations for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis.
16 Jul, 2021 | 10:28h | UTCNon-steroidal anti-inflammatory drugs, intravenous fluids, pancreatic stents, or their combinations for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic review and network meta-analysis – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)
Commentary on Twitter
New research – Akshintala et al – NSAIDs, intravenous fluids, pancreatic stents, or their combinations for the prevention of post-ERCP #pancreatitis: a systematic review and network meta-analysishttps://t.co/2Sh8WhqZRD#GITwitter #endoscopy #ERCP pic.twitter.com/nvAKXyPv13
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) June 30, 2021